|
BLZF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-16 |
| Normal-vs-Stage2 |
1.39639966256766E-10 |
| Normal-vs-Stage3 |
1.44195766438315E-12 |
| Normal-vs-Stage4 |
3.60940166643786E-11 |
| Stage1-vs-Stage2 |
2.383800E-01 |
| Stage1-vs-Stage3 |
3.549400E-01 |
| Stage1-vs-Stage4 |
2.438800E-01 |
| Stage2-vs-Stage3 |
6.904200E-01 |
| Stage2-vs-Stage4 |
9.663200E-01 |
| Stage3-vs-Stage4 |
7.126800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
6.378400E-04 |
| Normal-vs-Asian |
1.09240000378819E-08 |
| Caucasian-vs-AfricanAmerican |
5.048500E-02 |
| Caucasian-vs-Asian |
6.028600E-01 |
| AfricanAmerican-vs-Asian |
1.680180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.4432899320127E-15 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
2.352200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67565961106675E-12 |
| Normal-vs-Age(41-60Yrs) |
2.33146835171283E-15 |
| Normal-vs-Age(61-80Yrs) |
3.67861296979299E-12 |
| Normal-vs-Age(81-100Yrs) |
1.879010E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.615400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.257000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.883400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.732800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.376400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.322800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.699500E-02 |
| Classical-VS-Follicular |
1.550360E-02 |
| Classical-VS-Other |
1.153560E-01 |
| Classical-VS-Normal |
1.05319997167896E-09 |
| Tall-VS-Follicular |
9.185800E-01 |
| Tall-VS-Other |
4.284400E-01 |
| Tall-VS-Normal |
1.55359947129341E-10 |
| Follicular-VS-Other |
4.936800E-01 |
| Follicular-VS-Normal |
2.33590924381133E-12 |
| Other-VS-Normal |
1.800870E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.05499994798686E-09 |
| N0-vs-N1 |
6.461600E-01 |
|
|
